Clinical trial
Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell…
NCT00080886 · University of Nebraska, Other · Completed
Key facts
| NCT number | NCT00080886 |
|---|---|
| Title | Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma |
| Official title | A Phase II Trial Of BEAM/Rituximab/Autologous Hematopoietic Stem Cell Transplantation (AHSCT) For Patients With CD20 Positive Non-Hodgkin's Lymphoma |
| Lead sponsor | University of Nebraska, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug, Procedure |
| Interventions | rituximab, carmustine, cytarabine, etoposide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation |
| Enrollment | 68 |
| Start date | May 8, 2002 |
| Primary completion | Nov 1, 2005 |
| Completion | Mar 12, 2015 |
| First posted | Apr 8, 2004 |
| Last update posted | Oct 6, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: